Angel investors
What should an angel ask a syndicate lead about a healthcare software startup?
a healthcare software startup: Ask a syndicate lead who performs each diligence task, what information investors receive, and how the lead is compensated.
Ask a syndicate lead who performs each diligence task, what information investors receive, and how the lead is compensated. A familiar name or shared network does not resolve conflicts or establish that every material question was investigated.
Start with the decision
Map sourcing, analysis, references, document review, ongoing reporting, and investment authority. Ask which tasks are outside the lead's scope. Review compensation and related relationships through the actual disclosures and agreements.
The illustrative scenario
This is an educational workbook. The company or fund and all numerical inputs below are fictional. They are not ADIN results, customer claims, market benchmarks, or a forecast.
The fictional team is piloting an administrative scheduling product with a provider group. Staff use it in a narrow workflow, while procurement and data review determine whether a broader rollout is possible.
A clinic's enthusiasm does not resolve data handling, workflow ownership, or applicable regulatory questions. This example does not assume a particular legal classification or approval.
Turn the scenario into an evidence decision
Consider a review of a healthcare software startup in which a confident explanation arrives before the supporting records. Start with the first question in the table. Write down what an answer would change: the next interview, the experiment's scope, a request for specialist review, or a decision to wait. A question without a consequence can produce a longer document while adding little understanding.
Next, inspect the record named in the table and record its date, owner, permission boundary, and limitations. Review authorized workflow observations, procurement requirements, permissioned usage evidence, and specialist advice about applicable obligations. Avoid using identifiable patient information in a diligence packet. If the record contradicts the explanation, preserve both accounts and ask which definition, period, or workflow differs. Do not silently select the version that makes the opportunity look strongest.
Finish with a conditional statement: if the specified evidence supports the claim under these conditions, take the named next step; otherwise investigate the unresolved question. A syndicate can coordinate work while leaving participants responsible for their own decision. Do not equate membership, a lead's participation, or a deal memo with a guarantee of diligence quality or returns. This worked exercise is about the decision process. It does not assert that a fictional company has met a real diligence standard or that a template can authorize an investment.
| Item | Illustration |
|---|---|
| Decision question | Who owns diligence? |
| Case-specific constraint | A clinic's enthusiasm does not resolve data handling, workflow ownership, or applicable regulatory questions. This example does not assume a particular legal classification or approval. |
| Record to inspect | Review authorized workflow observations, procurement requirements, permissioned usage evidence, and specialist advice about applicable obligations. Avoid using identifiable patient information in a diligence packet. |
| Comparison to preserve | Compare the administrative workflow and rollout dependencies with the current process. Do not treat an operational pilot as clinical efficacy evidence. |
| Unresolved case question | Which workflow is actually in scope? |
Use this worksheet
Answer the questions with a source, date, owner, and next action. Mark an unknown as unknown. Use public or permissioned information and involve a qualified specialist when a question requires expertise beyond the team’s competence.
- Who owns diligence?
- What is independently verified?
- How is the lead compensated?
- Which conflicts are disclosed?
- What reporting follows the investment?
Questions specific to this scenario
- Which workflow is actually in scope?
- Who approves data access?
- What specialist review is needed?
Review authorized workflow observations, procurement requirements, permissioned usage evidence, and specialist advice about applicable obligations. Avoid using identifiable patient information in a diligence packet.
A concrete next test
Ask the authorized workflow owner to map a narrow administrative use case without disclosing patient information. Identify the data-access and procurement approvals needed for the next step. Keep operational adoption evidence separate from claims about clinical benefit or regulatory status.
Interpret the result
A syndicate can coordinate work while leaving participants responsible for their own decision. Do not equate membership, a lead's participation, or a deal memo with a guarantee of diligence quality or returns.
Compare the administrative workflow and rollout dependencies with the current process. Do not treat an operational pilot as clinical efficacy evidence.
Sources and method
These primary resources provide background for the concepts. The fictional scenario, calculations, and worksheet are ADIN educational examples; the sources do not report or validate those invented results. Reviewed October 11, 2026.